Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reached a new 52-week low during trading on Friday . The stock traded as low as $70.43 and last traded at $72.54, with a volume of 36727 shares traded. The stock had previously closed at $73.04.
Several analysts have commented on the stock. Cowen reaffirmed a “buy” rating and issued a $147.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 4th. JMP Securities set a $198.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Needham & Company LLC set a $152.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 27th. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 28th. Finally, BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, July 13th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average price target of $142.94.
The firm has a market cap of $8.69 billion, a price-to-earnings ratio of -13.36 and a beta of 2.54. The company has a current ratio of 13.22, a quick ratio of 13.22 and a debt-to-equity ratio of 0.02.
In related news, COO Yvonne Greenstreet sold 2,500 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $120.00, for a total transaction of $300,000.00. Following the transaction, the chief operating officer now owns 1,916 shares in the company, valued at approximately $229,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $137,000. Opera Trading Capital acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $137,000. Mutual of America Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 98.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 960 shares in the last quarter. IPG Investment Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $217,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 600.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock valued at $200,000 after acquiring an additional 1,953 shares in the last quarter. Institutional investors and hedge funds own 90.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2018/11/09/alnylam-pharmaceuticals-alny-hits-new-52-week-low-at-70-43.html.
Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Story: Fiduciary
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.